 Antigenic compositions and methods for using same |
| We claim: 1. An antigenic conjugate which is immunoreactive with anti-GM2 antibodies produced by ... |
|
| Stress proteins and uses therefor |
| The present invention relates to stress proteins and methods of modulating an individual's (such as ... |
|
| Methods for using heat shock proteins |
| OF THE PREFERRED EMBODIMENT Definitions For the purposes of the present invention, the term "toxin"... |
|
| Induction of a Th1-like response in vitro |
| The invention is based on the discovery that a cell sample containing naive lymphocytes can be ... |
|
| Method for producing cell-fushion type morbillivirus mutants |
| What is claimed is: 1. A method for reducing the cell-fusion ability of a virus comprising ... |
|
| Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
| An object of the present invention is to provide a method for enhancing the immunogenicity of an ... |
|
| Cationic oligopeptides having microbicidal activity |
| What is claimed is: 1. A method for inhibiting microbial growth in an environment susceptible to ... |
|
| Antibiotic cryptdin peptides and methods of their use |
| The present invention provides substantially purified cryptdin peptides having a consensus amino ... |
|
| Broad spectrum antimicrobial compounds and methods of use |
| The present invention provides indolicidin analogs, which are tryptophan-rich peptides that have ... |
|
|
Vaccines absorbable by the transmucosal way
| Details |
Inventors: Wyss, Rolando; Bizzini, Bernad; Volpato, Ivo;
Assignee: Grisotech S.A. (Soazza, CH)
Primary Examiner: Navarro; Mark
Assistant Examiner:
Attorney, Agent or Firm: Abelman, Frayne & Schwab
The main object of the present invention is to provide polysaccharide-coated antigens derivatized with lectins for pharmaceutical use. In the vaccines, polysaccharides are preferably selected from the group consisting of chitosan, low-molecular-weight and high-deacetylation-degree chitosan, methyl glycol chitosan, alginic acid, polymannuronic acid and salts or derivatives thereof. In the vaccines of the invention, antigens are microorganisms, infectious agents or constituents thereof, hormones, enzymes, proenzymes, narcotics, bioactive peptides, metabolites, biological precursors, cell constituents, allergens, and the lectins are of vegetable origin. |
|
DETAILED DESCRIPTION OF THE INVENTION The Applicants observed that when antigens, also of proteic nature, are coated with polysaccharides, they are absorbed by the mucosa and stimulate both local and humoral immunity.
Furthermore, when antigens are conjugated or derivatised with lectins, they are more effectively directed towards the mucosal cells, in particular, those expressing gangliosides GM1 and GM2 (M cells) and which are involved in the stimulation of the local and systemic immune response.
The incorporation in polysaccharides of antigens derivatised with lectins allows the exploitation of the directional effect of lectins that, being protected by the polysaccharide coating, do not produce concomitant undesired side effects.
It follows that the exploitation of the lectin directional effect, of the polysaccharide protection and transport, and of the immunomodulating effect of some polysaccharides.
e.
g.
chitosan, results in dosage control and elimination of side effects, if any, produced by lectins.
The major advantage of the vaccines of the invention is that they are absorbed by the oral and by the transmucosal way.
The vaccines according to the present invention are adsorbable either by direct local administration on external mucosae (nasal, pharingeal, rectal, vaginal, or intestinal mucosae) or by oral administration, the latter allowing the vaccines to reach the internal mucosae of the gastro-intestinal tract.
Furthermore, they are more efficacious than the corresponding coated- but non-conjugated vaccines, in that they are more efficiently directed towards the mucosal cells involved in the stimulation of the immune response.
It is, therefore, the main object of the present invention to provide polysaccharide-coated vaccines consisting of antigens derivatised with lectins, for pharmaceutical use.
According to the present invention polysaccharides form a protective coat surrounding the antigen-lectin conjugate and exert a triple action: they protect the antigen from the degradation due to proteolytic enzymes and gastric environment and, therefore, may be administered per os; isolate lectins from non-specific and potentially toxic absorption; and may have an immunostimulating effect
|
| Related patents |
|
|
Method of detecting mycoplasma infection in poultry and compositions therefor
OF THE INVENTION As used herein, the term "antigen" refers to a protein, polypeptide, or Coomassie blue staining band purified by the method described below and ...
|
|
|
FcεPE chimeric protein for targeted treatment of allergy responses, a method for its production and pharmaceutical compositions containing the same
OF THE INVENTION The Fc-PE chimeric protein according to the present invention has a number of advantages over the existing known drugs.: 1. Specificity: Fc-PE is ...
|
|
|
Targeting of dosages of medicine and therapeutic agents
The embodiments of the invention from which an exclusive property of privilege is claimed are as follows: 1. A method of treating a disease or condition in a human ...
|
|
|
Method of delivering a protein to poultry
In accordance with the present invention, it has been discovered that a protein can be administered to domestic birds by whole-body spraying of the birds with an ...
|
|
|
Attenuated recombinant rabies virus mutants and live vaccines thereof
OF THE INVENTION Preferred mutants according to the invention may be obtained by deleting residues 143 to 149 or 139 to 149 of the phosphoprotein (P) of rabies virus ...
|
|
|
Modified forms of Hepatitis C NS3 protease for facilitating inhibitor screening and structural studies of protease: inhibitor complexes
OF THE INVENTION The benefit of this invention is that the modified forms of HCV NS3 protease retain full activity, yet are highly amenable to biochemical ...
|
|
|
Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof
In its broadest aspect, the present invention is directed to a monoclonal antibody, or binding fragment thereof, which specifically binds to antigens sharing a common ...
|
|
|
Recombinant infectious laryngotracheitis virus and uses thereof
OF THE INVENTION The present invention provides a recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains ...
|
|
|
Growth differentiation factor-8
The present invention provides a cell growth and differentiation factor, GDF-8, a polynucleotide sequence which encodes the factor, and antibodies which are ...
|
|
|
Staphylococcus antigen and vaccine
It is therefore an object of the present invention to provide an antigen common to a majority of clinically-significant strains from multiple species of Staphylococcus. ...
|
|
|
Drugs 
